Joseph Chao
Overview
Explore the profile of Joseph Chao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
4184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al.
Nat Med
. 2025 Feb;
PMID: 39920391
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of...
2.
Ko A, Chao J, Noel M, Shankaran V, Sohal D, Crow M, et al.
Cancer Res Commun
. 2025 Feb;
5(2):349-357.
PMID: 39907035
Purpose: Neoadjuvant chemoradiation (NCRT) followed by surgical resection represents a standard approach for patients with locally advanced esophageal/gastroesophageal junction (GEJ) cancers. Sotigalimab is a high-affinity CD40 agonist antibody capable of...
3.
Park H, Klempner S, Chao J, Wainberg Z, Lukanowski M, Chenji S, et al.
Front Oncol
. 2024 Aug;
14:1419338.
PMID: 39206150
Introduction: The aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or...
4.
5.
Mahuron K, Sullivan K, Hernandez M, Chen Y, Chao J, Melstrom L, et al.
J Gastric Cancer
. 2024 Jul;
24(3):267-279.
PMID: 38960886
Purpose: The optimal treatment for gastroesophageal junction adenocarcinoma (GEJA) remains controversial. We evaluated the treatment patterns and outcomes of patients with locally advanced GEJA according to the histological type. Materials...
6.
Dayyani F, Chao J, Lee F, Taylor T, Neumann K, Cho M
Oncologist
. 2024 Jun;
29(8):721-e1088.
PMID: 38823034
Background: Most patients with metastatic gastroesophageal adenocarcinoma (mGEA) progress on immune checkpoint inhibitors (ICIs). Novel approaches to overcome resistance to ICI in mGEA are needed. Cabozantinib is a multi-tyrosine kinase...
7.
Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, et al.
J Clin Oncol
. 2024 May;
42(17):2080-2093.
PMID: 38723227
Purpose: Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus chemotherapy in patients...
8.
Botta G, Chao J, Ma H, Hahn M, Sierra G, Jia J, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38316518
Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment of...
9.
Cecchini M, Cleary J, Shyr Y, Chao J, Uboha N, Cho M, et al.
Br J Cancer
. 2023 Dec;
130(3):476-482.
PMID: 38135713
Background: Our preclinical work revealed tumour hypoxia induces homologous recombination deficiency (HRD), increasing sensitivity to Poly (ADP-ribose) polymerase inhibitors. We aimed to induce tumour hypoxia with ramucirumab thereby sensitising tumours...
10.
Fakih M, Salvatore L, Esaki T, Modest D, Lopez-Bravo D, Taieb J, et al.
N Engl J Med
. 2023 Oct;
389(23):2125-2139.
PMID: 37870968
Background: G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the...